Combining biomarkers to optimize patient treatment recommendations

Biometrics

Volumn 70, Issue 3, 2014, Pages 695-707

  Kang, Chaeryon ^a   Janes, Holly ^a   Huang, Ying ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Biomarker; Boosting; Model mis specification; Treatment selection

Indexed keywords

BIOMARKERS; DISEASES; FORECASTING; GENE THERAPY; ITERATIVE METHODS;

ADJUVANT CHEMOTHERAPY; BOOSTING; BOOSTING APPROACH; HORMONE THERAPY; MODEL MIS-SPECIFICATION; PERFORMANCE; PREDICTING OUTCOMES; SIMULATION STUDIES; TREATMENT EFFECTS; TREATMENT SELECTION;

CHEMOTHERAPY;

TUMOR MARKER;

BIOMETRY; BLOOD; BREAST NEOPLASMS; FEMALE; HUMAN; MALE; MORTALITY; OUTCOME ASSESSMENT; PREVALENCE; PROCEDURES; PROGNOSIS; REPRODUCIBILITY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; BIOMETRY; BREAST NEOPLASMS; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PREVALENCE; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84927690481     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/biom.12191     Document Type: Article

References (36)

1. Albain, K., Barlow, W., Ravdin, P., Farrar, W., Burton, G., Ketchel, S., Cobau, C., Levine, E., Ingle, J., Pritchard, K., Lichter, A., Schneider, D., Abeloff, M., Henderson, I., Muss, H., Green, S., Lew, D., Livingston, R., Martino, S., and Osborne, C. (2010a). Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. The Lancet 374, 2055-2063.
2. Albain, K., Barlow, W., Shak, S., Hortobagyi, G., Livingston, R., Yeh, I., Ravdin, P., Bugarini, R., Baehner, F., Davidson, N., Sledge, G., Winer, E., Hudis, C., Ingle, J., Perez, E., Pritchard, K., Shepherd, L., Gralow, J., Yoshizawa, C., Allred, D., Osborne, C., and Hayes, D. (2010b). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. The Lancet Oncology 11, 55-65.
3. Breiman, L., Friedman, J., Stone, C., and Olshen, R. (1984). Classification and Regression Trees. Wadsworth, Belmont, CA: Chapman & Hall/CRC.
4. Brinkley, J., Tsiatis, A., and Anstrom, K. (2010). A generalized estimator of the attributable benefit of an optimal treatment regime. Biometrics 66, 512-522.
5. Cai, T., Tian, L., Wong, P., and Wei, L. (2011). Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics 12, 270-282.
6. Chu, N., Ma, L., Liu, P., Hu, Y., and Zhou, M. (2011). A comparative analysis of methods for probability estimation tree. WSEAS Transactions on Computers 10, 71-80.
7. Claggett, B., Zhao, L., Tian, L., Castagno, D., and Wei, L. (2011). Estimating subject-specific treatment differences for risk-benefit assessment with competing risk event-time data. Harvard University Biostatistics Working Paper Series, 125.
8. Clark, G. (1995). Prognostic and predictive factors for breast cancer. Breast Cancer 2, 79-89.
9. Culp, M., Johnson, K., and Michailidis, G. (2012). ada: An R Package for Stochastic Boosting. R package version 2.0-3.
10. Efron, B. and Tibshirani, R. (1993). An Introduction to the Bootstrap, Vol. 57. London: CRC Press.
11. Etzioni, R., Kooperberg, C., Pepe, M., Smith, R., and Gann, P. (2003). Combining biomarkers to detect disease with application to prostate cancer. Biostatistics 4, 523-538.
12. Foster, J. C., Taylor, J. M. G., and Ruberg, S. J. (2011). Subgroup identification from randomized clinical trial data. Statistics in Medicine 30, 2867-2880.
13. Freund, Y. and Schapire, R. E. (1997). A decision-theoretic generalization of on-line learning and an application to boosting. Journal of Computer and System Sciences 55, 119-139.
14. Friedman, J., Hastie, T., and Tibshirani, R. (2000). Additive logistic regression: a statistical view of boosting (with discussion and a rejoinder by the authors). Annals of Statistics 28, 337-407.
15. Gunter, L., Zhu, J., and Murphy, S. (2007). Variable selection for optimal decision making. Artificial Intelligence in Medicine 4594, 149-154.
16. Gunter, L., Zhu, J., and Murphy, S. (2011a). Variable selection for qualitative interactions. Statistical Methodology 8, 42-55.
17. Gunter, L., Zhu, J., and Murphy, S. (2011b). Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate. Journal of Biopharmaceutical Statistics 21, 1063-1078.
18. Hastie, T., Tibshirani, R., and Friedman, J. (2001). The Elements of Statistical Learning: Data Mining, Inference and Prediction, Vol. 1. New York: Springer Series in Statistics.
19. Henry, N. and Hayes, D. (2006). Uses and abuses of tumor markers in the diagnosis, monitoring, and treatment of primary and metastatic breast cancer. The Oncologist 11, 541-552.
20. Janes, H., Brown, M., Pepe, M., and Huang, Y. (in press). An approach to evaluating and comparing biomarkers for patient treatment selection. International Journal of Biostatistics.
21. Janes, H., Pepe, M., and Bossuyt, P. (2014). A framework for evaluating markers used to select patient treatment. Medical Decision Making, 34, 159-167.
22. Janes, H., Pepe, M., Bossuyt, P., and Barlow, W. (2011). Measuring the performance of markers for guiding treatment decisions. Annals of Internal Medicine 154, 253.
23. Lu, W., Zhang, H., and Zeng, D. (2013). Variable selection for optimal treatment decision. Statistical methods in medical research, 22, 493-504.
24. Mebane, Jr., W. R. and Sekhon, J. S. (2011). Genetic optimization using derivatives: The rgenoud package for R. Journal of Statistical Software 42, 1-26.
25. Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F., Walker, M., Watson, D., Park, T., Hiller, W., Fisher, E., Wickerham, D., Bryant, J., and Wolmark, N. (2004). A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351, 2817-2826.
26. Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F., Watson, D., Bryant, J., Costantino, J., Geyer Jr, C., Wickerham, D., and Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology 24, 3726-3734.
27. Pepe, M., Cai, T., and Longton, G. (2005). Combining predictors for classification using the area under the receiver operating characteristic curve. Biometrics 62, 221-229.
28. Provost, F. and Domingos, P. (2003). Tree induction for probability-based ranking. Machine Learning 52, 199-215.
29. Qian, M. and Murphy, S. (2011). Performance guarantees for individualized treatment rules. Annals of Statistics 39, 1180.
30. Sekhon, J. S. and Mebane, Jr., W. R. (1998). Genetic optimization using derivatives: Theory and application to nonlinear models. Political Analysis 7, 189-213.
31. Song, X. and Pepe, M. (2004). Evaluating markers for selecting a patient's treatment. Biometrics 60, 874-883.
32. Therneau, T., Atkinson, B., and Ripley, B. (2012). rpart: Recursive Partitioning. R package version 4.0-1.
33. Vickers, A., Kattan, M., and Sargent, D. (2007). Method for evaluating prediction models that apply the results of randomized trials to individual patients. Trials 8, 14.
34. Zhang, B., Tsiatis, A., Laber, E., and Davidian, M. (2012). A robust method for estimating optimal treatment regimes. Biometrics 68, 1010-1018.
35. Zhao, X., Dai, W., Li, Y., and Tian, L. (2011). AUC-based biomarker ensemble with an application on gene scores predicting low bone mineral density. Bioinformatics 27, 3050-3055.
36. Zhao, Y., Zeng, D., Rush, A. J., and Kosorok, M. R. (2012). Estimating individualized treatment rules using outcome weighted learning. Journal of the American Statistical Association 107, 1106-1118.